Former Speaker Of The House Kevin Mccarthy Appointed To Anivive's Board Of Directors

(MENAFN- PR Newswire) McCarthy's
extensive
experience
in
government
and
advocacy
for
Valley
Fever will play a pivotal role in the launch of the world's first fungal vaccine.

LONG BEACH, Calif., Oct. 21, 2024 /PRNewswire/ -- Anivive Lifesciences, a leading technology-driven pet Pharmaceutical company, is proud to announce the appointment of former Speaker of the House Kevin McCarthy to its Board of Directors.

McCarthy's appointment underscores the significance of Anivive's breakthrough vaccine and the profound impact it will have on both pet and human health.
As co-founder of the Congressional Valley Fever Task Force and co-sponsor of the FORWARD Act,
McCarthy
has
been
instrumental
in
advancing
research, funding, and awareness to combat Valley Fever.

"Anivive's innovative approach to developing a vaccine for Valley fever is a game-changer," said Kevin McCarthy.

"We
are
excited
to
be
working with
Kevin
McCarthy,"
said
Dylan
Balsz, Founder and CEO of
Anivive. "His deep commitment to fighting Valley fever and his understanding of government processes will be invaluable as we prepare to launch the first vaccine for this devastating disease."

Nearly 100 million people and 30 million dogs live in areas impacted by Valley Fever. Over the past decade, infection rates have surged 600% and infected over a million people and their dogs.

Despite
its
widespread
impact and
billions
in
annual
healthcare
cost,
there
is
no existing vaccine to prevent the disease in humans or animals.

"Anivive's
innovative
approach to
developing
a
vaccine
for
Valley
fever
is
a game-changer," said Kevin McCarthy. "I am excited to join the Board and support their mission to bring this critical solution to those affected. Together, we can make a significant difference in combating this escalating health issue."

Anivive's fungal vaccine is the first to show efficacy and safety in over a dozen studies across multiple species. In June, the company received a $33 million contract from the National Institute of Allergy and Infectious Disease (NIAID) to scale manufacturing and fund clinical trials in man.

Anivive is targeting a 2025 launch for the canine vaccine and is working with the Unites States Department of Agriculture (USDA)
to help make the
vaccine
available for
dozens
of
endangered
zoo species
that
have
been impacted by the disease.

About
Anivive
Lifesciences

Anivive Lifesciences is a pet pharmaceutical company at the forefront of biotechnology, artificial intelligence, and veterinary medicine. Our mission is to transform veterinary healthcare by accelerating the development of novel, affordable treatments for life-threatening diseases in pets. Through our proprietary
AI
platform,
we
are
pioneering
first-in-class
therapeutics
in
Oncology, Antivirals, and
Antifungal Vaccines, setting new standards for innovation and excellence in the industry.

For
more
information,
please
visit
.

Forward-Looking
Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding Anivive's development programs, plans, and potential. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements.

SOURCE Anivive Lifesciences Inc.

MENAFN21102024003732001241ID1108802493